test prop cycle

Treatment of patients with hepatic or renal insufficiency should start with low doses under strict medical supervision. Some side effects observed in clinical trials were often associated with symptoms of depression, not to treatment test prop cycle .
General disorders: asthenia, malaise.
Violations of the heart: palpitation, tachycardia.
Violations of the gastrointestinal tract: abdominal pain, constipation, diarrhea, dry mouth, dyspepsia, nausea, , vomiting.
Disorders of the nervous system: irritability, anxiety, agitation, dizziness, insomnia or drowsiness, tremor, headache.
Disorders of the skin and subcutaneous tissue disorders: sweating.
Violations of the metabolism and nutrition: anorexia.
Violations of the vessels: orthostatic hypotension
Violations of the musculoskeletal and connective tissue disorders: arthralgia, myalgia.
Disorders of the nervous system: ataxia, extrapyramidal disorders.
Mental Disorders: State of confusion, hallucinations.
Violations of the genital organs and the breast: violation (delayed) ejaculation.
Violations of the skin and subcutaneous tissue: skin hypersensitivity reactions (including rash, pruritus, angioedema).
Violations of the liver: liver dysfunction (elevated liver enzymes).
Violations of the nervous system: convulsions.
Mental disorders: mania
Violations of the genital organs and the breast: galactorrhoea.
Violations skin and subcutaneous tissue disorders: photosensitivity reactions.

In addition to the side effects described in clinical studies during the post-marketing use of fluvoxamine it was reported the following side effects. The exact frequency can not be test prop cycle provided, and therefore classified as “unknown.”

Violations of the blood and lymphatic system: hemorrhage (eg, gastrointestinal bleeding, ecchymosis, purpura).

Disorders of the endocrine system: inadequate secretion of antidiuretic hormone.

Violations of the Metabolism and nutrition: hyponatremia, weight gain, weight loss.

Disorders of the nervous system: serotonin syndrome; phenomenon; like neuroleptic malignant syndrome; akathisia / psychomotor agitation; paresthesia; dysgeusia.

Mental disorders: during treatment with fluvoxamine or shortly after the end of the reported cases of suicidal ideation and suicidal behavior.

Violations of the kidney and urinary tract: urination disorders (including urinary retention, urinary incontinence, urinary frequency, nocturia and enuresis).

Violations of the genital organs and the breast: anorgasmia.

General disorders: drug withdrawal syndrome, including withdrawal symptoms in newborns.


The most characteristic symptoms are gastrointestinal disorders (nausea, vomiting and diarrhea), somnolence and dizziness. In addition, there are reports of violations. cardiac (tachycardia, bradycardia, hypotension), liver function disturbances, convulsions and coma.

Fluvoxamine has great therapeutic breadth dose safety against overdosage. Since its release to the market reports of deaths attributed to overdose of fluvoxamine alone, rarely observed. The highest registered dose of fluvoxamine adopted one patient was in ’12, this patient was completely cured. More serious complications were observed in cases of deliberate overdose of fluvoxamine in combination with other drugs.

No specific antidote to fluvoxamine does not exist: In case of overdose gastric lavage is recommended, which should be conducted as soon as possible after taking the drug, and symptomatic treatment. In addition, we recommend multiple dose activated charcoal, the appointment of osmotic laxatives if necessary. Forced diuresis or dialysis are not effective.

The interaction with other drugs.
Fluvoxamine can not be used in combination ).
Fluvoxamine largely inhibits cytochrome test prop cycle. Drugs which are largely metabolized by these isoenzymes, displayed slower and may have higher plasma concentrations, in the case of co-administration with fluvoxamine. This is particularly important for drugs that have a narrow range of therapeutic action. Patients in need of careful observation, it is recommended to adjust the dose of these drugs, if necessary.

Fluvoxamine has a minimal inhibitory effect on cytochrome  isoenzyme and probably does not affect the non-oxidative metabolism and renal excretion.